Impact of program scale and indirect effects on the cost-effectiveness of vaccination programs

Medical Decision Making

Volumn 32, Issue 3, 2012, Pages 442-446

  Ibuka, Yoko ^a,b   Paltiel, A David ^a   Galvani, Alison P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HITOTSUBASHI UNIVERSITY   (Japan)

Author keywords

epidemiological model; herd protection; resource allocation; scale dependency

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION; HEALTH CARE QUALITY; HUMAN; INFLUENZA; JAPAN; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH SERVICE; THEORETICAL MODEL; UNITED STATES; VACCINATION;

COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA VACCINES; INFLUENZA, HUMAN; JAPAN; MODELS, THEORETICAL; PROGRAM EVALUATION; PUBLIC HEALTH PRACTICE; UNITED STATES; VACCINATION;

EID: 84861820372     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X12441397     Document Type: Article

References (29)

1. Pradas-Velasco R, Antonanzas-Villar F, Martinez-Zarate MP. Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination. Pharmacoeconomics. 2008 ; 26 (1). 45-56
2. White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics. 1999 ; 103 (6). e73
3. Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics. 2000 ; 106 (5). 973-6
4. Luce BR, Zangwill KM, Palmer CS, et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics. 2001 ; 108 (2). E24
5. Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med. 2005 ; 118 (1). 68-77
6. Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine. 2006 ; 24 (7). 1035-43
7. Prosser LA, Bridges CB, Uyeki TM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis. 2006 ; 12 (10). 1548-58
8. Prosser LA, O'Brien MA, Molinari NA, et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmacoeconomics. 2008 ; 26 (2). 163-78
9. Anderson RM, May RM Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press ; 1991 :
10. Bridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2002 ; 51 (RR-3). 1-31
11. Chen SC, Liao CM. Probabilistic indoor transmission modeling for influenza (sub)type viruses. J Infect. 2010 ; 60 (1). 26-35
12. Chowell G, Miller MA, Viboud C. Seasonal influenza in the United States, France, and Australia: transmission and prospects for control. Epidemiol Infect. 2008 ; 136 (6). 852-64
13. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine: Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 ; 276 (14). 1172-7
14. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med. 2009 ; 151 (12). 829-39
15. Lee BY, Bacon KM, Donohue JM, Wiringa AE, Bailey RR, Zimmerman RK. From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination. Vaccine. 2011 ; 29 (11). 2149-58
16. Centers for Disease Control and Prevention. CDC vaccine price list 2011. Available from: http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm
17. US Department of Labor, Bureau of Labor and Statistics. Consumer price index: detailed report. Available from: http://www.bls.gov/cpi/#tables
18. Goldie SJ, Kim SY. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008 ; 26 (3). 191-215
19. Lugner AK, Mylius SD, Wallinga J. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Econ. 2010 ; 19 (5). 518-31
20. Bergman A, Hjelmgren J, Ortqvist A, et al. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scand J Infect Dis. 2008 ; 40 (9). 721-9
21. Isaacman DJ, Strutton DR, Kalpas EA, et al. The impact of indirect (Herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clin Ther. 2008 ; 30 (2). 341-57
22. Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ. 2008 ; 9 (1). 7-15
23. Vespa G, Constenla DO, Pepe C, et al. Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil. Rev Panam Salud Publica. 2009 ; 26 (6). 518-28
24. Rozenbaum MH, Hoek AJ, Hak E, Postma MJ. Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine. 2010 ; 28 (12). 2367-9
25. Johns B, Baltussen R. Accounting for the cost of scaling-up health interventions. Health Econ. 2004 ; 13 (11). 1117-24
26. Johns B, Torres TT. Costs of scaling up health interventions: a systematic review. Health Policy Plan. 2005 ; 20 (1). 1-13
27. Longini IM, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004 ; 159 (7). 623-33
28. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003 ; 7 (35). iii xi 1 - iv xiii 170
29. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999 ; 5 (5). 659-71